MARVAL Study Finds Diovan(R) Effective in Reducing Microalbuminuria, an Early Sign of Diabetic Kidney Disease.
/ADVANCE FOR RELEASE AT 3 P.M. EDT, TODAY/
/ADVANCE/SAN FRANCISCO, May 17 /PRNewswire/ --
New research shows the angiotensin II receptor blocker (ARB), Diovan(R) (valsartan), is more effective in reducing microalbuminuria (p<0.001), an early sign of diabetic kidney disease, compared to the calcium channel blocker calcium channel blocker
Any of a class of drugs that inhibit movement of calcium ions across a cell membrane, used in the treatment of cardiovascular disorders. , amlodipine. As part of the study, both treatment groups had blood pressure controlled to the same level. The results of the Microalbuminuria Reduction with Valsartan (MARVAL) trial were presented today at the 16th Annual Scientific Session of the American Society of Hypertension (ASH) in San Francisco. Diovan is well established as first-line treatment for hypertension and is marketed by Novartis Pharmaceuticals Corporation.
Microalbuminuria is an early sign of diabetic kidney disease (nephropathy) and occurs when kidneys deteriorate and leak protein into the urine. Left untreated, microalbuminuria may progress to end-stage renal disease (ESRD ESRD end-stage renal disease.
End-stage renal disease; chronic or permanent kidney failure.
Mentioned in: Dialysis, Kidney
ESRD End-stage renal disease, see there ), resulting in the need for dialysis or transplantation. Up to 40% of people with type 2 diabetes type 2 diabetes
See diabetes mellitus. (non-insulin dependent) develop ESRD and the annual cost of treating ESRD in the US is $14.5 billion. High blood pressure contributes to microalbuminuria and subsequent kidney failure and is the second most common cause of ESRD, as well as a leading risk factor for heart attack, heart failure, and other heart disease. About 60 to 65 percent of people with diabetes have hypertension.
MARVAL was a multi-center, double-blind, randomized, parallel study of 332 type 2 diabetes patients aged 35-75 with microalbuminuria with normal or high blood pressure. Patients were randomized to receive valsartan 80 mg once-daily or amlodipine 5 mg once-daily over 24 weeks. A target blood pressure of 135/85 mm/Hg was aimed for by dose doubling and the addition of bendrofluazide (a thiazide diuretic) and doxazosin (an alpha blocker) therapy. The study was designed to assess the blood-pressure-independent effects of Diovan vs. amlodipine on urinary albumin excretion rates (UAER), a measure of microalbuminuria. Geometric mean (lower and upper quartiles) in UAER mgram/min from baseline to end of study were for the valsartan group: 57.97(33.0,102.3) to 32.3(18.2,59.7) and for amlodipine: 55.4(34.3,84.6) to 50.7(31.8,85.6) (p<0.001). In addition, more patients returned to normal albuminuric al·bu·mi·nu·ri·a
The presence of albumin in the urine, sometimes indicating kidney disease.
al·bu status after 24 weeks with Diovan (29.9%) vs amlodipine (14.5%) (p=0.001). The Diovan and amlodipine groups experienced similar rates of blood pressure reduction. Mean systolic blood pressure Systolic blood pressure
Blood pressure when the heart contracts (beats).
Mentioned in: Hypertension decreased by 11.2 mm/Hg in Diovan patients and by 11.6 mm/Hg in amlodipine patients. Similarly, mean diastolic pressure decreased by 6.6 mm/Hg in Diovan patients compared with a decrease of 6.5 mm/Hg in patients who took amlodipine.
Many medical experts are calling for more aggressive treatment of high blood pressure to preserve optimal kidney function and prevent strokes and heart attacks in individuals whose kidneys have been damaged by diabetes. New guidelines issued by the National Kidney Foundation set a lower target for blood pressure of 125/75 mm/Hg in patients with proteinuria proteinuria /pro·tein·uria/ (-ur´e-ah) an excess of serum proteins in the urine, as in renal disease or after strenuous exercise.proteinu´ric
1. (abnormal amounts of protein in the urine). Notably, upon entering the study, 84% of MARVAL patients had blood pressure greater than or equal to 125/75 mm/Hg.
An earlier study by Muirhead et al also showed Diovan was effective in lowering microalbuminuria. This multi-center, randomized, double-blind, placebo-controlled study compared the safety and efficacy of Diovan 80 mg once-daily, Diovan 160 mg once-daily, the ACE inhibitor captopril captopril /cap·to·pril/ (kap´to-pril) an angiotensin-converting enzyme inhibitor used in the treatment of hypertension, congestive heart failure, and post–myocardial infarction left ventricular dysfunction. 25 mg three times daily and placebo in 122 type 2 diabetes patients with both normal and high blood pressure. The one-year study showed that Diovan was as effective in slowing the progressive rise of microalbuminuria as captopril. The total number of patients who experienced adverse effects was highest in the captopril group and lowest with Diovan 80 mg: 34.5% in the captopril group vs 22.6% in the Diovan 160 mg group vs 9.7% in the Diovan 80 mg group vs 13.8% in the placebo group. The incidence of trial drug-related dry cough was also highest in the captopril group.
Novartis is conducting one of the world's largest clinical trial programs with an ARB. The trials, which include the completed Val-HeFT (heart failure patients) and the ongoing VALUE (high-risk patients with hypertension) and VALIANT (post-myocardial infarction patients), examine the effect of Diovan beyond its existing indication for hypertension. Diovan is also the primary agent in a clinical trial involving adult type 2 diabetes patients with either normal or high blood pressure (ABCD-2V).
About three million patients worldwide take Diovan for high blood pressure and it is the fastest growing top 10 branded antihypertensive in the US today.
All ARBs carry a warning that the drug should not be used in pregnant women due to the risk of injury and even death to the fetus. The most common adverse events seen in controlled clinical trials with Diovan were headache and dizziness. For more information or a copy of the full prescribing information for Diovan, please visit the Novartis website at http://www.pharma.us.novartis.com/what/pi.html#cardio and select Diovan.
Novartis Pharmaceuticals Corporation is a member of the American Heart Association (AHA) Pharmaceutical Roundtable, a strategic coalition of leading pharmaceutical companies who support the AHA's mission by supporting its cardiovascular research and educational programs. Novartis is also a Corporate Member of the Heart Failure Society of America. Novartis is also working with the Association of Black Cardiologists on two education initiatives for African Americans: Operation H.U.S.H. (Hypertension Unchecked Silences Hearts) and "Children Should Know Their Grandparents, A Guide to a Healthy Heart."
Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including central nervous system disorders Nervous system disorders
A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency , organ transplantation, cardiovascular diseases, dermatological diseases, respiratory disorders, cancer and arthritis. The company's mission is to improve people's lives by pioneering novel healthcare solutions.
Located in East Hanover, New Jersey East Hanover Township is a township in Morris County, New Jersey, United States. As of the United States 2000 Census, the township population was 11,393. Incorporated in 1928, it is a largely middle to upper-income suburban community situated roughly 25 miles west of New York City. , Novartis Pharmaceuticals Corporation is an affiliate of the Novartis Group (NYSE NYSE
See: New York Stock Exchange : NVS), a world leader in healthcare with core businesses in pharmaceuticals, consumer health, generics, eye-care, and animal health. In 2000, the Group's ongoing businesses achieved sales of CHF CHF
In currencies, this is the abbreviation for the Swiss Franc.
The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 29.1 billion (USD USD
In currencies, this is the abbreviation for the U.S. Dollar.
The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 17.2 billion) and invested approximately CHF 4.0 billion (USD 2.4 billion) in R&D. Headquartered in Basel, Switzerland, the Novartis Group employs about 67,600 people and operates in over 140 countries around the world. For further information please consult http://www.novartis.com .
The foregoing press statement contains forward-looking statements that can be identified by terminology such as "could," "examine," "implication" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance, or achievements expressed or implied by such statements. In particular, management's expectations could be affected by, among other things, uncertainties relating to clinical trials.
MAKE YOUR OPINION COUNT -- Click Here